408 related articles for article (PubMed ID: 19319690)
61. Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model.
Xu R; Zhu H; Hu L; Yu B; Zhan X; Yuan Y; Zhou P
PLoS One; 2020; 15(5):e0227844. PubMed ID: 32470043
[TBL] [Abstract][Full Text] [Related]
62. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
[TBL] [Abstract][Full Text] [Related]
63. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
64. Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35.
Yu H; Hu YQ; Ip FC; Zuo Z; Han YF; Ip NY
Biopharm Drug Dispos; 2011 Apr; 32(3):140-50. PubMed ID: 21271607
[TBL] [Abstract][Full Text] [Related]
65. Studies on pharmacokinetic properties and absorption mechanism of phloretin: In vivo and in vitro.
Zhao YY; Fan Y; Wang M; Wang J; Cheng JX; Zou JB; Zhang XF; Shi YJ; Guo DY
Biomed Pharmacother; 2020 Dec; 132():110809. PubMed ID: 33049584
[TBL] [Abstract][Full Text] [Related]
66. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
Bachmeier CJ; Beaulieu-Abdelahad D; Ganey NJ; Mullan MJ; Levin GM
Biopharm Drug Dispos; 2011 May; 32(4):233-44. PubMed ID: 21446053
[TBL] [Abstract][Full Text] [Related]
67. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
68. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
Farrell RJ; Menconi MJ; Keates AC; Kelly CP
Aliment Pharmacol Ther; 2002 May; 16(5):1021-31. PubMed ID: 11966513
[TBL] [Abstract][Full Text] [Related]
69. Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor.
Song JS; Rho HJ; Park JS; Kim MS; Lee BH; Seo JW; Jeon DJ; Cheon HG; Ahn SH; Kwon KI; Bae MA
Drug Metab Pharmacokinet; 2011; 26(2):192-200. PubMed ID: 21206135
[TBL] [Abstract][Full Text] [Related]
70. Cellular Uptake and Transport Characteristics of FL118 Derivatives in Caco-2 Cell Monolayers.
Zhou Y; Hu W; Zhang X; Wang Y; Zhuang W; Li F; Li Q
Chem Pharm Bull (Tokyo); 2021; 69(11):1054-1060. PubMed ID: 34719586
[TBL] [Abstract][Full Text] [Related]
71. Intracellular Metabolomics Identifies Efflux Transporter Inhibitors in a Routine Caco-2 Cell Permeability Assay-Biological Implications.
Naseem A; Pal A; Gowan S; Asad Y; Donovan A; Temesszentandrási-Ambrus C; Kis E; Gaborik Z; Bhalay G; Raynaud F
Cells; 2022 Oct; 11(20):. PubMed ID: 36291153
[TBL] [Abstract][Full Text] [Related]
72. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062
[TBL] [Abstract][Full Text] [Related]
73. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
74. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
75. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.
Beéry E; Rajnai Z; Abonyi T; Makai I; Bánsághi S; Erdő F; Sziráki I; Herédi-Szabó K; Kis E; Jani M; Márki-Zay J; Tóth GK; Krajcsi P
Drug Metab Pharmacokinet; 2012; 27(3):349-53. PubMed ID: 22790065
[TBL] [Abstract][Full Text] [Related]
76. In vitro and in situ study on characterization and mechanism of the intestinal absorption of 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside.
Wang C; Zhou Y; Gong X; Zheng L; Li Y
BMC Pharmacol Toxicol; 2020 Jan; 21(1):7. PubMed ID: 31969193
[TBL] [Abstract][Full Text] [Related]
77. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
78. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
79. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
80. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers.
Annaert P; Van Gelder J; Naesens L; De Clercq E; Van den Mooter G; Kinget R; Augustijns P
Pharm Res; 1998 Aug; 15(8):1168-73. PubMed ID: 9706045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]